Toggle Summary
|
Celsion Corporation to Hold Second Quarter 2021 Financial Results and Business Update Conference Call on Thursday, August 12, 2021
LAWRENCEVILLE, N.J. , Aug. 05, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) , a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, announced today that the Company will host a conference call at 11:00 a.m.
|
View HTML
|
Toggle Summary
|
Results of Celsion’s OVATION 1 Study with GEN-1 in Patients with Advanced Ovarian Cancer Published in the Journal of Clinical Cancer Research
Data show d ose - dependent suppression of immun e- suppressive agents GEN-1 stimulate s the immune system through the production of CD4 and CD8 cells C hemotherapy R esponse Score tripled in the two highest doses of GEN-1 and is double that of chemotherapy alone LAWRENCEVILLE, N.J.
|
View HTML
|
Toggle Summary
|
Celsion Reports Data Safety Monitoring Board Recommendation to Continue Dosing Patients in the Phase II Portion of the OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer
OVATION 2 Study is 50% Enrolled; Excellent R0 Surgical Resection Noted Novel Gene- M ediated Immunotherapy is Safe and Demonstrates an Acceptable R isk/ B enefit W hen Administered O ver a Six-Month Period with Up to 17 D oses LAWRENCEVILLE, N.J.
|
View HTML
|
Toggle Summary
|
Celsion Corporation Expands Vaccine Advisory Board with the Addition of Dr. Dan H. Barouch and Dr. Luke D. Handke
VAB member experience with vaccine research and immunology will guide development of the PLACCINE platform for the prevention and treatment of infectious agents, including SARS-CoV-2 LAWRENCEVILLE, N.J. , July 15, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) , a clinical-stage
|
View HTML
|
Toggle Summary
|
Celsion GmbH Announces Commencement of Enrollment in Oxford University’s Phase 1 Study with ThermoDox® and Focused Ultrasound in Pancreatic Cancer
LAWRENCEVILLE, N.J. , July 01, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) , Celsion GmbH , a wholly owned subsidiary of Celsion Corporation , a clinical-stage biotechnology company, announces commencement of enrollment in Oxford University’s Phase I PanDox study with ThermoDox ® in
|
View HTML
|
Toggle Summary
|
Celsion Corporation Establishes Wholly Owned Subsidiary to Manage Investigator-Sponsored Development of ThermoDox®
Celsion GmbH will manage current and future cancer studies with Thermo D ox ® Celsion continues its strategic focus on the development of GEN-1 and PLACCINE LAWRENCEVILLE, N.J. , June 23, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) , a clinical-stage company focused on
|
View HTML
|
Toggle Summary
|
Celsion Corporation Enters into $10 Million Strategic Loan Facility with Silicon Valley Bank
Improvement to the Balance Sheet Leverages Strong Equity Structure Retires Debt and Gains Five Months of Operating Runway at Very Low Cost of Capital LAWRENCEVILLE, N.J. , June 21, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) , a clinical-stage company focused on DNA-based
|
View HTML
|
Toggle Summary
|
Celsion Appoints Christine A. Pellizzari to its Board of Directors
Brings extensive biopharmaceutical legal background to the Board Appointment increases the size of Celsion’s Board from seven to eight Directors LAWRENCEVILLE, N.J. , June 09, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage company focused on DNA-based immunotherapy
|
View HTML
|
Toggle Summary
|
Celsion Corporation Appoints Dr. Stacy R. Lindborg to its Board of Directors
25-year pharmaceutical industry executive brings broad drug development perspective Replaces Alberto Martinez , MD LAWRENCEVILLE, N.J. , June 08, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines,
|
View HTML
|
Toggle Summary
|
CELSION CORPORATION ANNOUNCES ADJOURNMENT OF ANNUAL MEETING
49% of S hares V oted, Q uorum N ot E stablished To Hold Annual Meeting Polls Remain Open Stockholders H olding U nvoted Proxies A re S trongly E ncouraged to V ote T heir S hares LAWRENCEVILLE, N.J. , June 04, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage
|
View HTML
|